A double-blind, placebo-controlled, dose–response study of the effectiveness and safety of lisinopril for children with hypertension

Open Access
Publisher Website
Google Scholar
Abstract
Background:Despite widespread use in hypertensive children, the safety and effectiveness of lisinopril had not been previously tested in a controlled study.Methods:This study explored the dose–response relationship and safety of lisinopril in 115 hypertensive children, aged 6 to 16 years. Patients were randomized in a double-blind fashion for 2 weeks to one of three doses by body weight at baseline: <50 kg: low (0.625 mg), middle (2.5 mg), high (20 mg), and ≥50 kg: low (1.25 mg), middle (5 mg), high (40 mg). The dose–response for lisinopril was evaluated by analyzing the change in slope in sitting diastolic and systolic blood pressure (BP) by dose after 2 weeks of therapy compared to baseline. Patients then entered a double-blind withdrawal, where patients were either switched to placebo or continued their current lisinopril treatment for up to 2 weeks. Patients completed period II when their BP returned to baseline. Antihypertensive effectiveness, between placebo and lisinopril was determined for all doses. Adverse events were carefully monitored.Results:There was a dose–response relationship between the lowest and each of the higher doses of lisinopril. Blood pressure in the placebo group increased after withdrawal of lisinopril. The dose–response relationship was consistent across all subgroups (ie, age, Tanner stage, ethnicity, gender).Conclusions:Lisinopril, once daily, is an effective and well-tolerated antihypertensive in children aged 6 to 16 years. An initial dose of 0.07 mg/kg, administered once daily, effectively lowered BP within 2 weeks. Blood pressure was reduced in a dose-dependent fashion.

This publication has 0 references indexed in Scilit: